Stockreport

Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (Duchenne) [Yahoo! Finance]

Edgewise Therapeutics, Inc.  (EWTX) 
PDF Food and Drug Administration (FDA) has granted Fast Track designation for EDG-5506 for the treatment of Duchenne. EDG-5506 is an investigational orally administered smal [Read more]